Aridhia Informatics

Aridhia Informatics specializes in providing a Digital Research Environment (DRE) that facilitates secure data sharing among clinical and research professionals, enhancing collaboration for advancing medical research. Founded in 2007, Aridhia Informatics is based in Edinburgh, UK, and operates as an independent company. The firm focuses on creating a collaborative platform for clinical and research professionals to enhance medical research. David Sibbald, the founder and CEO, has been instrumental in the company's development since inception.

The company raised GBP 1. 77 million in October 2013 from investors including Albion Capital and Scottish Equity Partners, bringing the total amount raised to GBP 1. 77 million with a post-money valuation of GBP 19. 13 million.

Aridhia’s core offering is the Aridhia Digital Research Environment (DRE), designed to enhance collaboration among clinical and research professionals. It enables secure data sharing and access for research hospitals, universities, and pharmaceutical companies, featuring a metadata catalog that supports FAIR data principles, customizable data governance frameworks, and secure workspaces. The DRE is utilized in various markets, including the UK, US, EU, Canada, and Australia, providing solutions to improve patient outcomes and accelerate drug development processes. Aridhia generates revenue primarily through subscription-based models for its Digital Research Environment (DRE) and FAIR Data Services.

Clients, including research hospitals and pharmaceutical companies, subscribe to these services for their research initiatives. The pricing structure accommodates both individual teams and larger enterprises, allowing customization based on specific research needs and supporting ongoing collaborations and data-sharing initiatives. Aridhia Informatics plans to leverage the GBP 1. 77 million raised in October 2013 to enhance its product offerings and expand its market reach.

The company aims to introduce new features within the DRE to further streamline research collaborations and is targeting new healthcare markets in Europe and North America by 2025. Recent funding will be allocated towards developing these new product features and enhancing marketing efforts to attract clients in these regions.